The stock's fall snapped a two-day winning streak.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

At the start of 2024, Virtualware launched a Strategic Plan to expand its North American footprint over the next three years. North American sales represented 36% of total revenue in 2024. The company ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Wall Street trading got off to a mixed start early on Wednesday as share price losses at tech giants Alphabet and AMD put ...

Brightcove's deal is one of several large acquisitions of local technology companies expected to close in 2025. Those include Markforged, which is set to be acquired by Waltham's Nano Dimension, and ...

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，他们收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性的生物制药公司，专注于为患有严重神经和神经退行性疾病的患者以及相关的治疗邻接患者发现、开发和提供全球创新疗法。该公司的核心增长领域包括多发性硬化症（MS）和神经免疫学 ...